By: Dana Farber Cancer Institute From: medicalxpress.com Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels, data from a clinical trial led by Dana-Farber/Brigham and Women’s Cancer Center suggests. The results of the trial, dubbed the IMpassion031 study, will be presented at the 2020 Congress of …
Atezolizumab Plus Chemotherapy Improves Responses in Triple-Negative Breast Cancer
By: Nichole Tucker From: targetedonc.com IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point. A statistically significant and clinically meaningful improvement in pathological complete response (pCR) was achieved with the combination of the monoclonal antibody atezolizumab (Tecentriq) plus albumin-bound paclitaxel (Abraxane) and nab-paclitaxel, followed by doxorubicin when administered to …